A Safety, Pharmacokinetic, and Pharmacodynamic Study of Once Daily Inhaled AZD8630 in Adults with Asthma

Study identifier:D6830C00004

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:2024-514213-35-00

Will Be Recruiting

Official Title

A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AZD8630, Administered Once Daily via Inhalation, for 2 Weeks, in Adults with Asthma on Medium-to-high Dose Inhaled Corticosteroids and Long-acting Beta-agonists

Medical condition

asthma

Phase

Phase 1/2

Healthy volunteers

No

Study drug

AZD8630

Sex

All

Estimated Enrollment

24

Study type

Interventional

Age

18 Years - 80 Years

Date

Study Start Date: 28 Jan 2025
Estimated Primary Completion Date: 22 May 2025
Estimated Study Completion Date: 22 May 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2025 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria